Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT06287684 Recruiting - Sepsis Clinical Trials

Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis

MENDSEP
Start date: September 13, 2023
Phase:
Study type: Observational [Patient Registry]

Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes, or subclasses, with important clinical implications. Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock. Against this backdrop, the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection.

NCT ID: NCT06281665 Not yet recruiting - Hypertension Clinical Trials

Treatment With Aspirin After Preeclampsia: TAP Trial

TAP
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

NCT ID: NCT06271031 Not yet recruiting - Sepsis Clinical Trials

Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection

CSM-BSI
Start date: March 1, 2024
Phase:
Study type: Observational

The goal of this study is to create a computer simulation of patients with bloodstream infection to understand how changes in healthcare policies and resources affect patient treatment. This simulation will help doctors and health-care decision makers make better choices in treating these patients and avoid overusing antibiotics that can lead to antibiotic resistance. Antibiotic resistance is when bacteria can't be killed by antibiotics anymore. Participants will not receive treatments as this is an observational study, but the study will involve: - Interviews with healthcare staff to understand patient care pathways. - Analysis of historical data on bacteria causing infections and antibiotic treatments. - A 30-day observational study to observe patient treatment for bloodstream infections.

NCT ID: NCT06267742 Recruiting - Sepsis Clinical Trials

Clinical Trial to Evaluate MDW for Early Detection of Sepsis

Start date: June 23, 2022
Phase:
Study type: Observational

This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill patients in Emergency Department (ED). This study is also aimed to provide study supporting data for the product to be marketed in China.

NCT ID: NCT06258252 Not yet recruiting - Sepsis Clinical Trials

Effect of Metabolic Dysfunction in Branched-chain Amino Acids on Cardiac Function in Patients With Sepsis

Start date: March 15, 2024
Phase:
Study type: Observational

The current project was designed to examine the effects of BCAA metabolic dysfunction on cardiac function in septic patients.

NCT ID: NCT06253585 Not yet recruiting - Sepsis Clinical Trials

Precision Resuscitation With Crystalloids in Sepsis

PRECISE
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Fluids are one of the most common treatments given to patients in the hospital. Fluids are especially important in treating patients with sepsis. Multiple clinical studies have compared the two main types of fluids used in sepsis (normal saline and balanced crystalloids). However, these studies have not found a clear benefit of one type of fluid versus the other. Which fluid should be given to which patient is an essential question because of the ubiquity of this intervention. Even a small difference in mortality could drastically change the standards of care given the national (and worldwide) scale of this intervention. The investigators have developed an algorithm that uses bedside vital signs (temperature, heart rate, respiratory rate, and blood pressure) to identify a group of patients (Group D) who have a significant mortality benefit from balanced crystalloids. The study randomizes adult patients in emergency departments across 6 Emory hospitals belonging to Group D to intervention versus usual care. The intervention arm involves a prompt to clinicians to use balanced crystalloids rather than normal saline.

NCT ID: NCT06253377 Active, not recruiting - Sepsis Clinical Trials

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

Start date: December 8, 2023
Phase:
Study type: Observational

It is an epidemiology study to explore outcomes in patients with acute kidney injury (AKI) and sepsis submitted to continuous renal replacement therapy (CRRT) with Oxiris™. Objectives: Describe the experience and outcomes in patients with sepsis and AKI treated receiving CRRT with the adsorption membrane filter Oxiris™

NCT ID: NCT06242561 Recruiting - Sepsis Clinical Trials

Quantification of Dilutional Anemia in the Initial Phase of Sepsis Management: Preliminary Retrospective Study

QUADS
Start date: January 1, 2024
Phase:
Study type: Observational

This is a single-center retrospective study conducted at Mercy hospital, aiming to investigate the correlation between changes in hemoglobin (Hb) levels and the volume of vascular refill administered during the first 48 hours.

NCT ID: NCT06240585 Not yet recruiting - Clinical trials for Gastroparesis and Sepsis

Gastroparesis as an Early Sign of Sepsis

Start date: June 1, 2024
Phase:
Study type: Observational

Upper gastrointestinal tract disorders, such as gastroparesis, are common in critically ill patients in the ICU, estimated at 60%. Gastroparesis symptoms include nausea, vomiting and abdominal pain. Risk factors for the development of gastroparesis include diabetes, surgical injury to the vagus nerve (such as certain types of bariatric surgery, and in the past - surgeries for patients who suffered from peptic ulcer), use of drugs that inhibit the activity of the digestive system such as opiates, anticholinergic drugs, sepsis, as well as being bedridden and inactive - are all common conditions in critically ill patients. There are different definitions for gastroparesis. One of the accepted definitions refers to gastric residual volume (GRV) over 200 ml at one measurement. Gastroparesis is found in some studies to be associated with increased morbidity and mortality in critically ill patients. As mentioned above, it is known that sepsis is a risk factor for gastroparesis. According to our experience based on treatment of a large number of septic patients, we have the impression that often gastroparesis is an early sign for the development of sepsis. We did not find any studies that tested this hypothesis. In this study we would like to investigate whether the development of gastroparesis in critical patients in intensive care can be a predictive sign for the development of sepsis.

NCT ID: NCT06238180 Recruiting - Sepsis Clinical Trials

Personalised Real-time Interoperable Sepsis Monitoring (PRISM)

PRISM
Start date: November 29, 2023
Phase:
Study type: Observational

The goal of this prospective observational study is to develop and utilize an Artificial Intelligence (AI) model for the prediction of postoperative sepsis in patients undergoing abdominal surgery. The main questions it aims to answer are: 1. Can a remote AI-driven monitoring system accurately predict sepsis risk in postoperative patients? 2. How effectively can this system integrate and analyze multimodal data for early sepsis detection in the surgical ward? Participants are equipped with non-invasive PPG-based wearable devices to continuously monitor vital signs and collect high-quality clinical data. This data, along with demographic and laboratory information from the Electronic Health Record (EHR) of the hospital, are used for AI model development and validation.